Amylin Said to Seek Buyers After Rejecting Bristol-Myers

Amylin Pharmaceuticals Inc., the maker of the diabetes drugs Bydureon and Byetta, is seeking a buyer after rejecting an unsolicited bid from Bristol-Myers Squibb Co., two people with knowledge of the matter said.

Amylin has hired Credit Suisse Group AG and Goldman Sachs Group Inc. to help solicit possible offers, said one of the people, who asked not to be identified because the talks are private.